Cheng, Feixiong http://orcid.org/0000-0002-1736-2847
Zhao, Junfei
Wang, Yang
Lu, Weiqiang http://orcid.org/0000-0003-1349-6597
Liu, Zehui
Zhou, Yadi
Martin, William R. http://orcid.org/0000-0003-0616-0462
Wang, Ruisheng
Huang, Jin
Hao, Tong http://orcid.org/0000-0001-7908-3256
Yue, Hong http://orcid.org/0000-0003-4347-3193
Ma, Jing
Hou, Yuan
Castrillon, Jessica A.
Fang, Jiansong
Lathia, Justin D.
Keri, Ruth A.
Lightstone, Felice C. http://orcid.org/0000-0003-1465-426X
Antman, Elliott Marshall http://orcid.org/0000-0002-0808-9199
Rabadan, Raul http://orcid.org/0000-0001-7946-9255
Hill, David E. http://orcid.org/0000-0001-5192-0921
Eng, Charis http://orcid.org/0000-0002-3693-5145
Vidal, Marc
Loscalzo, Joseph http://orcid.org/0000-0002-1153-8047
Funding for this research was provided by:
American Heart Association (D700382, CV-19, AHA CRADA TC02274.0)
Foundation for the National Institutes of Health (U01 HG007690, P50 GM107618, U54 HL119145, K99 HL138272, R00 HL138272, 3R01AG066707-01S1, R01AG066707, P50 HG004233, U41 HG001715, P50 HG004233, U41 HG001715)
VeloSano Pilot Program (Cleveland Clinic Taussig Cancer Institute
the Sondra J. and Stephen R. Hardis Endowed Chair in Cancer Genomic Medicine at the Cleveland Clinic, and an ACS Clinical Research Professor.
Article History
Received: 27 February 2020
Accepted: 22 December 2020
First Online: 8 February 2021
Competing interests
: J.L. is the scientific cofounder of Scipher Medicine, Inc., a startup company that uses network medicine to identify biomarkers for disease and specific pathway targets for drug development. M.V. is a shareholder and scientific advisor of seqWell, Inc. and founder and scientific advisor of Gloucester Marine Genomics Institute, Inc. The other authors declare no competing interests.